The spread of coronavirus continues both in Italy and globally.

For this reason, to protect the health of its employees and at the same time prevent the spread of the virus as much as possible, OPIS promptly adopted multiple precautionary measures listed in a special protocol distributed to all employees, in compliance with the Inter-ministerial Protocol issued by the Government on March 14, 2020.

Thanks to the measures introduced, 90% of OPIS employees have adopted smart working, while the remaining 10% who cannot carry out their activities at home are able to work at the company facilities thanks to the optimal safety standards implemented within the offices.

Thanks to the measures introduced, OPIS can ensure business continuity in line with government directives.

In these times of great difficulty on a global level, OPIS is at the forefront of the fight against coronavirus, collaborating in studies testing new therapeutic approaches in patients with COVID-19 who develop respiratory complications.

OPIS has always made available all of its know-how, experience and professionalism so that its partners can be supported in the clinical development of drugs quickly and in compliance with the provisions in force.

Distant but united we are ready to undertake new and challenging projects to develop valid therapies for COVID-19.

SOLNATIDE, the therapeutic molecule solnatide developed by APEPTICO for the treatment of various forms of life-threatening acute pulmonary dysfunction and pulmonary oedema in ARDS patients, has been approved by the Italian Medicines Agency and the Ethics Committee of the National Institute for Infectious Diseases (Lazzaro Spallanzani-Rome) for the treatment of COVID-19 patients suffering from pulmonary oedema and acute respiratory distress syndrome.

Bernhard Fischer, CEO of APEPTICO, stated: “After the initial approval in Austria, this is the second European country approving solnatide for the emergency treatment of severely injured COVID-19 patients. Together with OPIS we will make solnatide available for COVID-19 patient treatment in Italy, one of the European Countries most affected by the new coronavirus infections.”

Aldo Poli, CEO of OPIS added: “We are proud to participate to the clinical development of solnatide in patient affected with COVID-19. At this time of great difficulty on a global level, OPIS is pleased to be at the forefront of the fight against coronavirus, collaborating with APEPTICO with the aim of providing a new therapeutic approach in patients with COVID-19 who develop respiratory complications.

Further information on the compassionate use program for solnatide is available at the following link: https://www.aifa.gov.it/programmi-di-uso-compassionevole-covid-19

READ PRESS RELEASE